PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-0.79
Negative P/E while Biotechnology median is -1.50. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
1.95
P/B 1.25-1.5x Biotechnology median of 1.53. Guy Spier would scrutinize if premium reflects better asset utilization.
-6.63
Negative FCF while Biotechnology median P/FCF is -6.26. Seth Klarman would investigate cash flow improvement potential.
-6.63
Negative operating cash flow while Biotechnology median P/OCF is -6.06. Seth Klarman would investigate operational improvement potential.
1.95
Fair value ratio 1.25-1.5x Biotechnology median of 1.53. Guy Spier would scrutinize if premium reflects durable advantages.
-31.73%
Negative earnings while Biotechnology median yield is -7.93%. Seth Klarman would investigate path to profitability.
-15.08%
Negative FCF while Biotechnology median yield is -8.36%. Seth Klarman would investigate cash flow improvement potential.